Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

Completed · Phase 3 · Has a placebo group

Conditions studied: Type II; Diabetes

In brief

To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.

Key facts

Study ID

NCT02984644

Run by

The University of Texas Health Science Center at San Antonio

People needed

30

Starts

2017-09-06

Expected to finish

2019-11-16

Last updated by the study team

2019-12-18

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• T2DM according to ADA criteria-HbA1C < 8.0%
• BMI = 25-35 kg/m2
• Subjects must be in good general health as determined by physical exam, medical history, blood chemistries, CBC, TSH, T4, EKG and urinanalysis
• Body weight has been stable (± 3 lbs) over the preceding three months
• Do not participate in an excessively heavy exercise program
• Taking stable dose (more than 3 months) of monotherapy or combination therapy with metformin and/or a sulfonylurea

You may not qualify if…

• Subjects taking drugs known to affect glucose metabolism (other than metformin and sulfonylurea) will be excluded
• Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine >1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg will be excluded

Where it is running

• University of Texas Health Science Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.